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PHeart Failure
hanges in Brain Natriuretic Peptide Levels and
ioelectrical Impedance Measurements After
reatment With High-Dose Furosemide and
ypertonic Saline Solution Versus High-Dose
urosemide Alone in Refractory Congestive Heart Failure
Double-Blind Study
alvatore Paterna, MD,* Pietro Di Pasquale, MD,. Gaspare Parrinello, MD,† Ersilia Fornaciari, MD,*
rancesca Di Gaudio, MD,‡ Sergio Fasullo, MD, Marco Giammanco, MD,§ Filippo M. Sarullo, MD,¶
iuseppe Licata, MD†
alermo, Italy
OBJECTIVES The aim of this study was to evaluate the effect of a new treatment for refractory congestive
heart failure (CHF) on brain natriuretic peptide (BNP) plasma levels and hydration station.
BACKGROUND The study was aimed at evaluating the effects of the combination of high-dose furosemide and
small-volume hypertonic saline solution (HSS) in refractory CHF patients.
METHODS A total of 94 patients (34 women/60 men) with refractory CHF (age 55 to 80 years) were
enrolled. They had to have an ejection fraction35%, serum creatinine2 mg/dl, blood urea
nitrogen60 mg/dl, a reduced urinary volume, and a low natriuresis (500 ml/24 h and60
mEq/24 h, respectively). Patients were divided (double-blind) into two groups: group 1 (18
women/30 men) received an intravenous furosemide (500 to 1,000 mg) plus HSS twice a day
in 30 min. Group 2 (16 women/30 men) received an intravenous bolus of furosemide (500 to
1,000 mg/twice a day) alone, for four to six days. At entry, body weight, blood pressure, heart
rate, and laboratory parameters were checked during hospitalization; BNP levels were
measured on admission, 6 and 30 days after discharge, while on admission and 6 days after,
impedance plethysmography was performed. The HSS group received 120 mmol of Na intake
versus 80 mmol in non-HSS group. Fluid intake of 1,000 was given to both groups.
RESULTS The groups were similar for clinical characteristics. A significant increase in daily diuresis and
natriuresis was observed in HSS group, p  0.05. The BNP values showed significant
intragroup and intergroup differences, 6 and 30 days after treatment. The patients from the
HSS group reached a better hydration state than the non-HSS group after six days. In
addition, the HSS group showed a significant reduction in hospitalization time and
readmission rate.
CONCLUSIONS Our data show that the HSS group reached dry weight more rapidly, a significantly faster
reduction in BNP levels, shorter hospitalization stay, and lower incidence in readmissions in
the 30-day study period. (J Am Coll Cardiol 2005;45:1997–2003) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.059College of Cardiology Foundation
C
m
c
a
A
d
p
H
p
d
i
c
fl
despite recent advances in the treatment of congestive heart
ailure (CHF) and the results in randomized trials, many
atients continue to present with signs and symptoms that
re refractory to treatment with digoxin, diuretics,
See page 2004
ngiotensin-converting enzyme (ACE) inhibitors, and
ther vasodilators, and the prevalence and incidence of
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Manuscript received November 28, 2004; revised manuscript received January 6,
005, accepted January 26, 2005.HF is increasing progressively worldwide (1–3). The
anagement of patients with advanced CHF classically
onsists in sodium intake restriction together with physical
ctivity and treatments that include digitalis, diuretics, and
CE inhibitors (4). Diuretics, particularly potent loop
iuretics, have long been accepted as first-line treatment of
atients with severe CHF and extreme fluid retention (5,6).
owever, a lack of response to diuretics is a common event,
articularly in elderly patients with advanced disease. When
iuretic resistance occurs, proposed therapeutic options
nclude higher doses or constant diuretic infusion (7),
oncomitant dopamine infusion to increase renal blood
ow, potentiating diuretic activity (8), and a combination of
ifferent classes of diuretics, providing synergistic effects
9–11). Previously, we showed the safety and tolerability of
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Changes in BNP Levels and Bioelectrical Impedance June 21, 2005:1997–2003he combination of high-dose furosemide associated with
mall-volume hypertonic saline solution (HSS) infusion
lus normosodic diet (12,13) and that this combination in
omparison with an intravenous high-dose infusion of
urosemide as bolus plus iposodic diet in patients with
evere CHF determined a significant reduction of hospital-
zation time, the maintenance of the achieved New York
eart Association (NYHA) functional class at discharge,
he reduction of readmissions to hospital for CHF worsen-
ng (14), and a significant mortality rate reduction (55%
urvival after 48 months) (15). Because natriuretic peptides
ave been shown to be a useful part of epidemiological
tudies and clinical trials in advanced heart disease (16–19),
nd these peptides have been shown to be very powerful
rognostic markers (7,20–26), we performed a randomized
ouble-blind study to verify the effects of HHS treatment
lus high-dose furosemide on brain natriuretic peptide
BNP) plasma levels at entry, 6 days, and 30 days after
reatment and on hydration state at entry and 6 days after in
atients with advanced CHF (NYHA functional class IV)
n comparison with an intravenous high-dose infusion of
urosemide as bolus.
ETHODS
he rationale and design of the HHS study have been
eported previously (12–15).
atient population. From January 2000 to January 2002,
4 patients were consecutively admitted to hospital with
YHA functional class IV refractory CHF.
ligibility criteria. Patients had to have, according to the
efinition of refractory CHF (1) and according to Framing-
am criteria and NYHA functional classification for CHF
2), uncompensated CHF (dyspnea, weakness, lower limb
dema, or anasarca), NYHA functional class IV that was
nresponsive to treatment with oral high doses of furo-
emide up to 250 to 500 mg/day and/or combinations of
iuretics (thiazide, loop diuretic, and spironolactone), ACE
nhibitors (captopril 75 to 150 mg/day), digitalis, beta-
lockers, and nitrates and to be under this therapy at least
wo weeks before the study and before hospitalization. The
atients were judged unresponsive, when they showed
uring the treatment as above reported, a reduction of urine
olume and constant increase of body weight (BW) and
mpairment of clinical signs of CHF, as above reported,
espite the increase of furosemide and the combination of
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
BIA  bioelectrical impedance analysis
BNP  brain natriuretic peptide
BW  body weight
CHF  congestive heart failure
HSS  hypertonic saline solution
NYHA  New York Heart Associationther diuretics. Additionally, they had to have a left ven-
f
ricular ejection fraction35%, serum creatinine2 mg/dl,
lood urea nitrogen 60 mg/dl, a reduced urinary volume
500 ml/24 h), and a low natriuresis (60 mEq/24 h)
espite receiving the established treatments. None of the
atients were taking nonsteroid anti-inflammatory drugs.
ach patient provided written informed consent before
tarting the study.
andomization. Baseline characteristics of the study sub-
ects are shown in Tables 1 and 2.
Double-blind randomization was carried out using a
reliminary computer algorithm, and the assignment of
atient was decided at the time of admission by an inde-
endent physician, before performing complete clinical
xamination and laboratory measurements. The solutions
ere prepared before by an independent nursing team
irected by an independent physician. The solutions con-
ained different concentrations of NaCl and two different
oses of furosemide (250 or 500 mg). These infusions were
umbered and were blinded to physicians treating the
atients. The same smaller doses were prepared without
aCl addition and numbered as in the previous group. In
ddition, the nursing team prepared a bolus of furosemide
500 or 1,000 mg) or placebo, which was also numbered.
hen randomization was decided, the treating physicians
eceived the solutions without any identification sign. The
ouble-blind was revealed only when randomization was
nished. The randomization staff, in this way, gave the
reatment according to baseline characteristics of patients,
nd according to the protocol of treatment previously
eported, without informing about solution composition to
he physicians performing the study. The final data and
linical results were collected by another independent phy-
ician and, after analysis, were given to the appropriate
erson. All patients included in the study, after randomiza-
ion, underwent a complete physical examination, with a
areful check of CHF signs and symptoms, including
easurement of BW (in the morning before breakfast),
upine and standing blood pressure (mean of three measure-
ents), and heart rate. Fasting blood samples were drawn to
etermine serum Na, K, Cl, bicarbonate, albumin, uric acid,
reatinine, urea, and glycemia on a daily basis during
ospitalization and continuing until a clinically compen-
ated state was obtained. The total daily output of urine was
able 1. Clinical Characteristics and Etiology of CHF
Furosemide
Without HSS
Furosemide
With HSS
atient number 94 46 48
ender, F/M 34/60 16/30 18/30
HF etiology
CAD 46 22 24
HHD 27 13 14
DCM 21 11 10
AF 15 8 7
F  atrial fibrillation; CAD  coronary artery disease; CHF  congestive heart
ailure; DCM dilatative cardiomyopathy; HHD hypertensive heart disease; HSS
hypertonic saline solution.
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June 21, 2005:1997–2003 Changes in BNP Levels and Bioelectrical Impedanceollected for Na, K, and Cl measurements. Chest X-ray,
lectrocardiogram, and echocardiogram (to obtain ejection
raction according to the modified Simpson’s rule, which
ses two cross-section views (four- and two-chamber apical
iews) were obtained before the beginning of the therapy
nd again at the time of hospital discharge and 30 days after.
he BNP plasma levels were measured on admission, 6
ays, and 30 days after discharge. The evaluation of the
ydration state was performed on admission and six days
fter. The compensation fluid balance was detected by a
etrapolar impedance plethysmography (BIA-101, Akern,
irenze, Italy). The bioelectrical parameters of resistance
nd reactance were measured using an electric alternating
urrent flux of 800 A and an operating frequency of 50
Hz. The accuracy was checked with a calibration circuit of
nown impedance (R 380, Xc 47, 1% error; where
 resistance and Xc  reactance). Whole body imped-
nce measurements were taken by using a standard position
f outer and inner electrodes on the right hand and foot.
he entire procedure was performed according to the
ndications of the National Institutes of Health technology
ssessment conference statements (27). For each patient a
atabase was created that included anthropometric data
height, weight, and body mass index). Bioelectrical imped-
nce analysis (BIA) evaluates some basic properties of the
ody by measuring resistance, reactance (reactance is a form
f opposition that electronic components exhibit to the
assage of alternating current because of capacitance or
nductance; in some respects, reactance is like an alternating
urrent counterpart of direct current and indicates an
bsolute amount of body cell mass), and phasic angle (phase
ngle is an indicator of cellular health and integrity; a low
able 2. Clinical and Laboratory Parameters Before (at Entry) an
Furosemide Without HS
Entry 6 Days
atient number 46 46
ge (yrs) 74.5  6 —
BP (mm Hg) 146  22 118  11
BP (mm Hg) 82  14 77  11
R (beats/min) 83  15 82  11
jection fraction 30.2  3 31.1  4
ody weight (kg) 75.8  15 67.1  14
iuresis (ml/24 h) 425  129 1,660  515*
erum Na (mEq/l) 134.9  7 130.1  3*
erum K (mEq/l) 4.8  0.6 3.5  0.4*
rinary Na (mEq/24 h) 54.5  12.4 129  32*
rinary K (mEq/24 h) 59  29 96  35
erum glucose (mg/dl) 91  21 96  24
UN (mg/dl) 56.1  3.5 99  11*
erum creatinine (mg/dl) 1.55  0.05 1.98  0.2*
ric acid (mg/dl) 6.6  2.1 9.8  3.7
erum albumin (g/dl) 4.2  0.7 4.18  0.6
ospitalization (days) 10.5  2.6
eight (kg) lost 8.1  2.4
ata are expressed as mean  SD. *p  0.0001, differences between the two group
BUN  blood urea nitrogen; DBP  diastolic blood pressure; HSS  hypertonhase angle is consistent with an inability of cells to store rnergy and an indication of breakdown in the selective
ermeability of cellular membranes; a high phase angle is
onsistent with large quantities of intact cell membranes and
ody cell mass; phase angle is proportional to the ratio of
eactance and resistance; the range of phase angle in the
uman body is 1° to 20°). In healthy and ill individuals total
ody water and fat-free mass can be estimated using
ormulas that include BIA variables and often also individ-
al’s general characteristics. As an alternative, BIA values
re evaluated, as such, in comparison to reference values
btained in the general population (as resistance and reac-
ance percentiles, or bivariate resistance-reactance confi-
ence limits). It is well known that BIA reflects variation in
otal body water and the ratio between extracellular water
nd total body water; BIA is used to estimate the volumes of
ody fluid compartments. Electrical current is conducted by
ody water, and impeded by other body components. The
pposition to flow of electrical current is called impedance.
mpedance is proportional to the length of the conductor,
nd inversely proportional to the cross-sectional area. Be-
ause volume is simply length multiplied by area, impedance
s directly related to the volume of the body fluid. Fluid
ompartment volume measures are a useful part of body
omposition assessment for several reasons. Estimates of
xtracellular fluid volume together with total body water
olume allow calculation of intracellular fluid volume. In-
racellular fluid volume correlates strongly with body cell
ass. The recruited patients were randomized into two
roups (double-blind fashion): group 1 received an intrave-
ous 30-min infusion of furosemide (500 to 1,000 mg) plus
SS (150 ml of 1.4% to 4.6% NaCl) twice a day, and
aintained a normosodic diet (120 mEq NaCl); group 2
ter Six Days of Treatment
Furosemide With HSS
p Value Entry 6 Days p Value
48 48
74.7  8 —
0.0001 145  21 115  11 0.0001
0.06 80  13 75  11 0.045
0.7 83  12 78  8 0.01
0.22 30.1  3 32  5 0.026
0.006 76.0  16 65.8  15 0.002
0.0001 410  141 2,250  652* 0.0001
0.0001 133.8  6 142.3  3.4* 0.0001
0.0001 4.4  0.4 3.9  0.3* 0.0001
0.0001 49.1  12 197  22* 0.0001
0.0001 64  21 86  22 0.0001
0.29 97  23 95  22 0.66
0.0001 62  4 64  9.5* 0.18
0.0001 1.51  0.1 1.45  0.05* 0.0001
0.0001 6.8  2.8 9.6  3.2 0.0001
0.88 3.9  0.5 3.8  0.5 0.33
6.57  2.3 0.0001
10.9  4.1 0.0001
ays after the treatment.
e solution; HR  heart rate; SBP  systolic blood pressure.d Af
Seceived an intravenous infusion of furosemide (500 to
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Changes in BNP Levels and Bioelectrical Impedance June 21, 2005:1997–2003,000 mg) as bolus twice day, without HSS, and maintained
n iposodic diet (80 mEq NaCl) for a period of four to six
ays. Daily dosage of furosemide was defined considering
iuretics, urinary volume, blood pressure values, and severity
f signs and symptoms of congestion. The dose of HSS was
etermined in each patient (first group) according to the
ollowing schedules: for serum Na values125 mEq/l HSS,
oncentration was 4.6%. For serum Na values between 126
Eq/l and 135 mEq/l HSS, concentration was 3.5%, and,
or serum Na values 135 mEq/l, HSS concentration
aried between 1.4% and 2.4%. KCl (20 to 40 mEq)
ntravenous was administered to prevent hypokaliemia.
uring the study period, the patients received ACE inhib-
tors, digitalis, nitrates, and beta-blockers (when possible) as
reviously reported. During the treatment and after hospital
ischarge, the daily dietary sodium intake was 120 mEq for
he first group and 80 mEq for the second group, with a
uid intake of 1,000 ml daily in both groups. An accurate
ssessment of BW (in the morning before breakfast) and
4-h urinary volume was performed every day. Serum and
rinary laboratory parameters were measured daily until
eaching a clinical compensated state, considered as a
hange in NYHA functional class to at least IIb and the
ccomplishment of ideal BW, calculated by the Lorenz
ormula. Once the clinical compensated state was reached,
he intravenous administration of furosemide (both groups)
nd HSS was stopped (first group) and replaced with oral
urosemide administration (250 to 500 mg/twice a day) and
ral KCl supplementation and the best therapy continued
ithout changes after the discharge along with the standard
herapy (ACE inhibitors [captopril 75 to 150 mg/day],
igitalis [0.125 to 25 mg/day], antialdosterone, beta-
lockers, and nitrates) in both groups. The double-blind
spect of the study was continued at discharge and for the
ubsequent 30 days. During the study period, other treat-
ents were not added to those administered.
tatistical analysis. The results are expressed as mean
alues  SD. The statistical analysis was performed using
he two-tailed t test to identify differences between the
roups and analysis of variance for repeated measures with
onferroni correction for intragroup data. The number of
omparisons included in the Bonferroni correction was
hree for each group. Nominal data were analyzed by
hi-square test; a p value 0.05 was considered to be
ignificant.
ESULTS
inety-four (female/male: 34 to 59) with refractory CHF of
ifferent etiologies (46 coronary artery disease, 27 hyperten-
ive heart disease, 21 dilated cardiomyopathy, aged 55 to 81
ears, met the entry criteria and continued the study in
ccordance with the study protocol (Table 1). The patients
howed at entry: 94 orthopnea, 94 extreme fatigue on effort,
4 third heart sound, 94 marked peripheral edema, 94
epatic enlargement, 94 bronchial rales, 79 pleural effusions,
D1 pericardial effusion, 48 ascites. A prominent improve-
ent in clinical parameters such as dyspnea, lower limb
dema, anasarca, and weakness was obtained in all patients
tudied. In fact, patients from the two groups and patients
n anasarca (ascites, pleural, and pericardial effusion) expe-
ienced complete resolution of this state (evaluated clinically
nd by X-ray and echocardiography) after the treatment that
esulted in the rapid relief of dyspnea, weakness, and
atigue. Before the study, natriuresis was low in most
atients despite that they were receiving high oral doses of
urosemide and/or combinations of diuretics, suggesting the
resence of a resistance to furosemide action. A significant
ncrease was observed in daily diuresis in both groups. The
atriuresis was increased in both groups as well as serum Na.
erum K was decreased significantly, but the value remained
n the normal range in both groups (Table 2). In addition,
he renal function was controlled also after discharge did not
how significant differences with those obtained after six
ays of treatment (Table 3). The HSS group showed a
igher amount of Na excreted (approximately 200 mEq
a/24 h vs. 130 mEq Na/24 h in non-HSS group, p 
.001). The amount of Na administered intravenously each
ay ranged from approximately 1.6 g (300 ml/day of 1.4%
ypertonic saline) to 5.4 g (300 ml/day of 4.6% hypertonic
aline) for HSS group plus 2.8 g (120 mEq) Na/24 h
normosodic diet) versus 1.8 g (80 mEq) Na/24 h (iposodic
iet) in non-HSS group. Body weight was reduced, and the
eduction was proportional to increased urinary volume. As
reviously reported (14,15), the changes in NYHA func-
ional class, with most study patients going from class IV to
lass II, was evidenced in both groups. The serum creatinine
nd serum uric acid concentrations significantly increased
fter therapy in both groups. The patients did not complain
f any major discomfort during treatment and tolerated well
he intravenous infusion. No side effects of this therapy, in
articular hearing loss or tinnitus were observed in HSS
atients. In both groups, systolic and diastolic values of
lood pressure were decreased without important clinical
anifestations, and HR was corrected to normal values
Tables 2 and 4). Table 5 shows the changes of BNP plasma
evels in both groups. The BNP values showed significant
ntragroup differences (values on admission vs. 6 days and 30
ays after). In addition, we observed that plasma levels of
able 3. Laboratory Parameters of Renal Function at Discharge
Furosemide
Without HSS
Furosemide
With HSS
Discharge Discharge p Value
atient number 46 48
iuresis (ml/24 h) 1,550  355 2,180  545 0.0001
rinary Na (mEq/24 h) 119  21 188  25 0.0001
rinary K (mEq/24 h) 93  29 87  23 0.26
UN (mg/dl) 98  12 65  10 0.0001
erum creatinine (mg/dl) 1.97  0.2 1.55  0.05 0.001
ric acid (mg/dl) 10.8  4.3 10.3  3.7 0.54ata are expressed as mean  SD.
BUN  blood urea nitrogen; HSS  hypertonic saline solution.
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June 21, 2005:1997–2003 Changes in BNP Levels and Bioelectrical ImpedanceNP were significantly lower in HSS group in comparison
ith non-HSS group, 6 days and 30 days after treatment.
he evaluation of hydration state evidenced that patients
rom HSS group reached, after 6 days, a better hydration
tate in comparison with non-HSS group. Tables 6 and 7
how the BIA variables that were very stable, the coefficient
f variation on serial measurements being 1.7% for resis-
ance and 2.1% for reactance, which increased after treat-
ent, especially in the HSS group; phase angle, which also
ncreased after treatment, showed a mean coefficient of
ariation of 1.2% and a maximum variation of 0.3°. Patients
ere discharged from the hospital after 6 to 12 days. The
SS group showed a significant reduction in hospitalization
ime and readmission rate in agreement with our previous
esults (14,15).
ollow up. During the 30-day double-blind follow-up
eriod, no patients from the first group were hospitalized or
ied, while 12 patients from the second group were read-
itted to the hospital for clinical signs of heart failure, and
hey presented, at entry, higher functional class than at
ischarge (NYHA functional class III), while the remaining
atients maintained the same NYHA functional class
chieved at the time of hospital discharge. Three patients
ied during the 30-day study period in the second group
sudden death and irreversible heart failure). Only six
atients received beta-blockers (carvedilol) in both groups.
ll patients continued ACE inhibitors as previously re-
orted (captopril 75 to 150 mg/day). During the follow-up,
he outpatients were controlled, and the treatments (where
ecessary) were corrected according to clinical status and
aboratory measurements (reduction and/or increase of di-
able 4. Results of the Study (30 Days): Side Effects,
eadmissions, and Mortality
Furosemide
Without HSS
Furosemide
With HSS
p
Value
atient number 46 48
ender, F/M 16/30 18/30
ide effects (tinnitus) 11 0 0.05
eadmissions 12 0 0.05
ortality 3 0
udden death 2 0
SS  hypertonic saline solution.
able 5. Changes in BNP Levels During the Study Period
30 Days)
BNP Values (pg/ml)
p Value
Furosemide
Without HSS
Furosemide
With HSS
dmission 1,265  515* 1,212  491* 0.6
days 468  251*† 343  196*† 0.008
0 days 552  284*† 312  165*† 0.0001
value 0.0001 0.0001
ata are expressed as mean  SD. Differences between groups were performed by t
est. *p 0.0001, differences between the results obtained on admission vs. 6 days and
0 days after treatment in each group; †pNS, differences between 6 days vs. 30 daysg
fter treatment in both groups (analysis of variance).
BNP  brain natriuretic peptide; HSS  hypertonic saline solution.retics, fluid intake, and Na/K intake, BNP levels, and BIA
arameters). No correction of therapy was carried out in all
atients but in readmitted patients who received open
reatments after readmission. Echocardiographic data dur-
ng follow-up showed a nonsignificant slight improvement
n ejection fraction in all patients.
ISCUSSION
he mechanism(s) explaining the efficacy of the proposed
ombined infusion in the treatment of severe and refractory
HF may comprise the instantaneous mobilization of
xtravascular fluid into the intravascular space through the
smotic action of HSS (12–15,28,29) and the rapid excre-
ion of this volume by the action of extracellular fluid
xpansion itself and by the action of intravenous furosemide
nfusion. Further, HSS, by a demonstrated increase in renal
lood flow (30), may facilitate the action of diuretics and
elp overcome an established diuretic resistance, frequently
bserved in these patients, related to CHF itself (24–26) or
o age-associated decrease in renal function (22,23). Re-
arding the kidney and its circulation, patients with CHF
eveal a picture that strikingly resembles that defined in
esponse to hemorrhage. Thus, given the well-documented
nfluence of the renal blood supply on Na handling and the
eversal of the antinatriuresis when renal perfusion is in-
reased in these patients, it seems likely that the renal
ascular response participates in the Na retention in patients
ith advanced disease (31); HSS infusion determines a
able 6. Bioimpedance Analysis Parameters in Decompensated
eart Failure Patients Before and After Intravenous Treatment
ith HSS Plus Furosemide
Admission 6 Days After p Value
eight 76.08  16.67 65.82  15.38 0.002
MI 29.12  5.2 26.92  5.05 0.038
esistance () 409.9  112.4 503.6  114 0.0001
eactance () 27.2  15.6 40.4  16.7 0.0001
h.A 3.59  1.2 4.45  1.42 0.002
/h 259.4  81.6 317.8  80.5 0.0001
c/h 17.2  9.9 25.6  11.1 0.001
alues are expressed as mean  SD.
BMI  body mass index; HSS  hypertonic saline solution; Ph.A  phase angle;
/h  resistance/height ratio; Xc/h  reactance/height ratio.
able 7. Bioimpedance Analysis Parameters in Decompensated
eart Failure Patients Before and After Intravenous Treatment
ith Furosemide Without HSS
Admission 6 Days After p Value
eight 75.85  15.78 67.12  14.18 0.006
MI 29.6  5.9 27.71  5.81 0.125
esistance () 411.1  117.5 483.4  116.2 0.004
eactance () 28.2  16.3 38.6  13.7 0.001
h.A 3.61  1.3 4.15  1.32 0.051
/h 261.2  83.4 298.7  76.3 0.027
c/h 17.7  10.2 23.6  10.1 0.006
ata are expressed as mean  SD.
BMI  body mass index; HSS  hypertonic saline solution; Ph.A  phase an-
le; R/h  resistance/height; Xc/h  reactance/height.
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Changes in BNP Levels and Bioelectrical Impedance June 21, 2005:1997–2003apid elevation of extracellular NaCl concentration with a
onsequent rise in osmotic pressure, plasmatic volume
xpansion, instantaneous fluid mobilization into the vascu-
ar compartment, increased renal blood flow (32,33). Addi-
ionally, fluid shifted out of erythrocytes and endothelial
ells to the extracellular space leads to a reduction in
apillary hydraulic resistance (29).The rapid expansion of
xtracellular fluid volume is responsible for the decreased
lasma and peritubular oncotic pressure that, along with an
ncreased peritubular hydrostatic pressure, enhances the
rinary Na excretion by a reduction in proximal Na reab-
orption (34). The simultaneous administration of furo-
emide at high doses adds an important hydrosaline renal
xcretion, because the increment in renal blood flow allows
urosemide’s concentration in the Henle’s loop to be opti-
al. In fact, HSS administration seems to potentiate the
iuretic action of furosemide, and possibly to help overcome
stablished resistance to diuretics with no need of higher
oses and, consequently, limit electrolyte disturbance and
ther side effects (hypotension, tinnitus, etc). The most
mportant results of our study were the rapid compensation
btained in these CHF class IV patients, and mainly the
aintenance of the achieved NYHA functional class at
ischarge, and a reduction of readmissions to hospital for
HF worsening (12–15). The significant and rapid reduc-
ion in BNP values confirms the clinical data. In fact, the
ain stimulus for BNP peptide synthesis and secretion is
ardiac wall stress (35). Because increased wall stress is a
ommon denominator of many cardiac diseases, it follows
hat BNP levels may serve as biochemical markers of these
tates. Because of its fast induction and specific expression
n overt heart failure, BNP seems the most promising
atriuretic peptide as a marker of left ventricular dysfunc-
ion, which makes it an important component of cardiac
are. The more significant and rapid BNP reduction in HSS
atients is probably due to rapid and important plasmatic
olume reduction and subsequent cardiac wall stress. It is
ossible that the therapeutical effects of this treatment are
ot only mediated by the direct effects on renal hemody-
amics, but also by neurohormones modulation. It is pos-
ible that the strict control performed in these patients
llowed us to correct the treatments, as well as the possi-
ility that the Na intake (120 mEq) allowed a continued
esponse to diuretics. This last mechanism could also justify
he maintenance of the reduction in BNP levels observed 30
ays after discharge. This hypothesis is the most probable
ecause the conventionally treated patients, as previously
eported, were strictly controlled, but readmissions were
ignificantly higher (14,15) than normosodic diet patients.
n addition, our previous reports were single-blind studies,
hile the present study was performed in double-blind
ashion. The results of the hydration state also confirm the
linical and BNP findings. In fact, patients receiving HSS
howed a more significant rapid improvement in hydration
tate than patients not receiving HSS and normosodic diet
36). We also used BIA because this method is a safe,oninvasive, rapid, and inexpensive technique, and is well
orrelated with other techniques in detecting body compo-
ition such as magnetic resonance imaging (37), deuterium
ilution technique (38), and thermodilution (39,40). We
hink that diuretics augment natriuresis by impeding the
eabsorption of Na that has filtered through the glomerulus.
fter a few days of once-daily dosing with a high-potency
iuretic formulation, the increase in 24-h natriuresis that
ccurs after the first dose disappears or becomes markedly
ttenuated; this is usually referred to as braking phenome-
on. The processes involved in the increase in Na reabsorp-
ion that account for the braking phenomenon have not
een fully clarified (41,42). Our patients differed from the
eart failure population reported in many heart failure
tudies because of the higher blood pressure, higher ejection
raction, and larger net diuresis. In conclusion, our data
uggest that the combination of high doses of furosemide
ith HSS determines a more rapid compensation. In fact,
ystematic data on changes in bioelectrical variables occur-
ing in HF patients before and after treatment show that
atients receiving HSS reached their dry weight more
apidly than those not receiving HSS solution. In addition,
significantly faster reduction in BNP levels, shorter hos-
italization stay, and lower incidence in readmissions in the
0-day period of study in CHF patients were also observed.
ll the three parameters investigated, clinical data, BNP
evels, and bioelectrical variables, showed that HSS solution
ith a high-dose of furosemide plus a normosodic diet can
btain a significant improvement in advanced CHF pa-
ients.
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